Amitriptyline/Perphenazine

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published December 9, 2025•Updated December 9, 2025•Reviewed December 9, 2025

Clinical summary for Amitriptyline/Perphenazine: This med is a two-in-one: an older antidepressant plus an older antipsychotic. That combo can help when depression is mixed with anxiety/agitation, but the tradeoff is side effects. People often feel calmer and sleepier, but they can also get dry mouth, constipation, dizziness when standing, brain fog, and (from the antipsychotic part) restlessness or stiffness. It has major safety warnings, interacts with lots of meds (especially MAOIs and sedatives), and it’s generally avoided in older adults.

What It's Used For

Amitriptyline/perphenazine is used in psychiatry for people who aren’t just “sad” or “anxious,” but wired-up, agitated, and struggling to function—where a medication that calms the nervous system and treats depression at the same time is being considered. It’s not approved for pediatric use.

Primary Indications

Unipolar Major Depressive Disorder (MDD) with moderate to severe anxiety and/or agitationDepression with prominent anxiety, insomnia, or agitation where sedation is part of the clinical goalSchizophrenia with depressive symptoms

Off-Label Uses

Not applicable for this medication.

What People Feel

Real talk: this is an “older school” combo med, and people often notice it in their body quickly—sometimes in helpful ways, sometimes in annoying ways.

Calm / Sedation (often early)

"My brain finally stopped sprinting—like the buzzing got turned down."

How Fast It Works

This combo can calm agitation and help sleep earlier than it improves depression. Think: calming first, mood next.

First few doses

Sedation/calm can show up early (especially if you’re sensitive)

First 1-2 weeks

Anxiety/agitation may soften as the nervous system settles

2-6+ weeks

Antidepressant effect is more likely to be noticeable and consistent

Day-to-day duration

Effects depend on dose timing (often divided doses) and how sedating it is for you

If you miss doses or stop abruptly

You can get rebound symptoms or a discontinuation syndrome

How Well It Works

Clinical improvement in depression with anxiety/agitation

Not applicable for this medication.

vs Not applicable for this medication.

This medication is used when the clinical target is a specific cluster: depression plus significant anxiety/agitation (sometimes with insomnia). The “win” looks like fewer spirals, less agitation, improved sleep, and better day-to-day function—without unacceptable side effects like severe dizziness, heart rhythm issues, or movement symptoms.

Critical Safety Information

This medication has boxed warnings about suicidality risk (especially under 25) and increased mortality in elderly patients with dementia-related psychosis.

→If you’re under 25 (or caring for someone who is), take the suicidality warning seriously: monitor mood, agitation, insomnia, irritability, impulsivity, and sudden behavior changes—especially early on and after dose changes.
→If you feel intense inner restlessness, stiffness, tremor, or new abnormal movements, contact your prescriber quickly. Don’t “tough it out.”
→Go slow when standing up. Dizziness/fainting can happen, and falls are a real risk.
→Constipation and urinary retention can become urgent problems—tell your clinician early and manage proactively.
→Avoid alcohol and other sedatives unless your prescriber explicitly reviewed the combo. Sedation and impairment stack.
→This medication is not for dementia-related psychosis. In older adults with memory problems, this is usually a ‘no’ unless there’s a very specific reason.

Side Effects

Most common issues in real life: sedation, dry mouth/constipation, dizziness from blood pressure drops, and (from perphenazine) movement side effects like restlessness or stiffness.

Common Things People Notice

Sleepiness or a sedated, slowed-down feeling
Dry mouth (xerostomia)
Constipation, blurred vision, urinary retention (anticholinergic effects)
Dizziness when standing (orthostatic hypotension) and fall risk
Restlessness (akathisia), stiffness, tremor, or other EPS
Sexual side effects or hormonal symptoms from prolactin changes (less predictable but possible)

Common Side Effects

Frequency not defined

Sedation / Slowed Thinking— Many people feel calmer and sleepier early on. That can be helpful for agitation/insomnia, but it can also cause brain fog and daytime impairment—especially during titration.

Frequency not defined

Dry Mouth (Xerostomia)— Dry mouth is common with amitriptyline. It’s annoying, but it also matters medically (teeth/gum issues). Hydration, sugar-free gum/lozenges, and dental care help.

Frequency not defined

Orthostatic Hypotension / Dizziness— Blood pressure can drop when standing. If you’re getting lightheaded, near-fainting, or falls, that’s a dose-limiting side effect.

Frequency not defined

EPS (Restlessness, Stiffness, Tremor)— Perphenazine can cause movement side effects. Akathisia can feel like unbearable inner agitation and is sometimes mistaken for worsening anxiety—tell your clinician fast.

Frequency not defined

Constipation / Urinary Retention— These can become serious. If you can’t pee, or you go days without a bowel movement with abdominal pain, treat it as urgent.

⚠️ Serious Side Effects

Suicidal ideation or worsening depression, especially early in treatment or after dose changes
Tardive dyskinesia: potentially persistent involuntary movements (risk increases with duration and cumulative dose)
Neuroleptic malignant syndrome (NMS): fever, severe rigidity, confusion, autonomic instability (medical emergency)
Life-threatening arrhythmias or conduction abnormalities, especially with cardiac disease or overdose
Blood dyscrasias: leukopenia, neutropenia, agranulocytosis (sometimes fatal); seek care for fever, sore throat, infection symptoms
Aspiration pneumonia risk in vulnerable populations due to dysphagia/esophageal dysmotility
Hyponatremia/SIADH, particularly in older adults (confusion, weakness, falls)
Myocarditis (postmarketing reports)
Hyperthermia and impaired temperature regulation (heat intolerance, dehydration risk)

Critical Drug Interactions

This combination has meaningful interaction risk. The biggest red flags are MAOIs and anything that adds sedation, anticholinergic burden, or heart rhythm risk.

With: MAO inhibitors (MAOIs)

Risk: Dangerous interaction risk; requires washout period.

Action: Do not use together. Allow 14 days between stopping an MAOI and starting amitriptyline/perphenazine, and allow 14 days between stopping this medication and starting an MAOI.

With: Alcohol, opioids, sedating antihistamines, sleep meds, benzodiazepines

Risk: Additive CNS depression: heavy sedation, impaired coordination, accidents, respiratory risk in vulnerable patients.

Action: Avoid or use only with careful clinician review. If combined, use the lowest effective doses and monitor closely.

With: Other anticholinergic medications (e.g., diphenhydramine, many bladder meds, some antipsychotics/TCAs)

Risk: Anticholinergic toxicity: severe constipation/ileus, urinary retention, confusion/delirium, blurred vision, overheating.

Action: Minimize anticholinergic stacking. If you’re already constipated, retaining urine, or confused—this combo is a problem.

With: Medications that increase QT/arrhythmia risk

Risk: Higher risk of conduction abnormalities/arrhythmias, especially with cardiac disease or electrolyte issues.

Action: Review full med list for QT risk. Consider ECG monitoring when clinically indicated.

With: Medications that lower seizure threshold

Risk: Increased seizure risk in susceptible patients.

Action: Use caution in seizure disorder, brain injury, heavy alcohol use history, or when combining multiple threshold-lowering meds.

With: CYP2D6 poor metabolizer status or strong CYP2D6 inhibitors

Risk: Higher plasma concentrations at usual doses can raise side-effect risk.

Action: Consider lower dosing and slower titration; monitor tolerability closely.

Safe Discontinuation

Don’t stop this medication abruptly unless a clinician tells you to for a safety emergency. Both components can cause rebound and withdrawal-style symptoms. The safer approach is usually a gradual taper, tailored to how long you’ve been on it, your dose, and your symptom history.

Key Points

Antidepressant discontinuation syndrome can include nausea, dizziness, headaches, sweating/chills, sleep disruption, vivid dreams, anxiety, irritability, and “electric shock” sensations.
Stopping antipsychotics suddenly can cause withdrawal symptoms and rebound symptoms: agitation, anxiety, insomnia, GI symptoms, tremor, dyskinesia, and—in some cases—rebound psychosis.
Risk factors for difficult discontinuation: higher dose, longer duration, abrupt stop, and a history of relapse or severe baseline symptoms.
A practical taper is typically stepwise dose reduction over weeks (sometimes longer), slowing down if withdrawal symptoms or relapse signs appear.
If severe EPS, NMS symptoms, severe arrhythmia symptoms, or dangerous confusion develops, seek urgent medical evaluation—those situations can require immediate medication changes under supervision.

Dosing Information

Adult Dosing

older adult: Avoid use when possible (high-risk in older adults). If used: start low (e.g., 1 tablet amitriptyline 10 mg/perphenazine 4 mg PO 3 to 4 times daily) and titrate cautiously; lower-range dosing is often sufficient in late-onset schizophrenia/psychosis

maoi switching: Allow 14 days between discontinuing an MAOI and starting this medication; allow 14 days between stopping this medication and starting an MAOI

mdd anxiety max: Maximum daily dose: amitriptyline 200 mg/perphenazine 16 mg per day in 2 to 4 divided doses

renal adjustment: Refer to individual agents; use caution in renal impairment and monitor for increased adverse effects

hepatic adjustment: Use caution; some experts recommend reducing initial and maintenance amitriptyline doses by ~50% in hepatic impairment with cautious adjustments based on response/tolerability; some recommend maximum amitriptyline 100 mg/day in hepatic impairment

mdd anxiety initial: 1 tablet PO 3 to 4 times daily of either amitriptyline 25 mg/perphenazine 2 mg OR amitriptyline 25 mg/perphenazine 4 mg; alternative: 1 tablet (amitriptyline 50 mg/perphenazine 4 mg) PO twice daily

mdd anxiety titration: Adjust dose based on response and tolerability; use the smallest effective total daily dose and reassess side effects frequently

schizophrenia depressive max: Maximum daily dose: amitriptyline 200 mg/perphenazine 16 mg per day in 2 to 4 divided doses

schizophrenia depressive initial: 2 tablets (amitriptyline 25 mg/perphenazine 4 mg) PO 3 to 4 times daily

predominantly anxiety lower start: If anxiety is predominant, consider lower initial dosing: 1 tablet (amitriptyline 10 mg/perphenazine 4 mg) PO 3 to 4 times daily

schizophrenia depressive titration: Adjust dose based on response and tolerability; monitor closely for EPS, orthostasis, sedation, and anticholinergic effects

Simple Explanation

This medication is usually dosed multiple times per day. The calming/sedating effect can show up early, while antidepressant benefits often take longer. Because the side-effect burden can be heavy (dry mouth/constipation, dizziness, and movement side effects), dose changes are often limited by tolerability rather than by ambition.

Pregnancy, Breastfeeding, Special Groups

This medication is generally avoided in pediatric patients and often avoided in older adults. Pregnancy and breastfeeding decisions are individualized and should involve risk/benefit discussion using the details of the individual components.

👶Pregnancy

Adverse events were not observed in animal reproduction studies per the provided notes. Clinical decision-making should follow the risk profile of the individual agents, the severity of illness, and safer alternatives when available.

🤱Breastfeeding

Amitriptyline and perphenazine are present in breast milk. Breastfeeding is not recommended by the manufacturer; if considered, it requires careful clinician oversight and infant monitoring.

👧Children & Adolescents (Under 18)

Not approved for pediatric patients. Antidepressants carry increased risk of suicidal thinking/behavior in children/adolescents/young adults; this combination is not FDA-approved for children.

👴Older Adults (65+)

Generally avoid. Amitriptyline has strong anticholinergic effects and can cause sedation and orthostatic hypotension. Perphenazine (antipsychotic) is potentially inappropriate in older adults due to stroke risk, cognitive decline, and mortality risk (especially in dementia-related psychosis). Falls, delirium, and hyponatremia risk are key concerns.

🔬Liver Impairment

Use caution because clearance can be reduced and plasma concentrations increased. A conservative approach uses lower initial and maintenance dosing with cautious titration; some expert guidance suggests reducing amitriptyline dosing substantially and keeping the maximum lower in hepatic impairment.

💧Kidney Impairment

Use caution in renal impairment. Dosing specifics are typically guided by the individual components and by observed tolerability.

Clinical Monitoring

Suicidality and clinical worsening: monitor closely, especially early in therapy and during dose changes; involve family/caregivers when appropriate
Mental status and alertness: sedation, confusion, delirium risk (especially in older adults or with sedative combinations)
Blood pressure and orthostatics: monitor for orthostatic hypotension and fall risk
EPS: assess every visit; repeat at ~4 weeks after initiation and after dose changes; use a formal rating scale at least annually (or every 6 months if high risk)
Tardive dyskinesia: assess every visit; use a formal rating scale at least annually (or every 6 months if high risk)
Weight/BMI: monitor every visit for first 6 months, then quarterly; consider waist circumference at baseline and annually when metabolic risk is a concern
Fasting glucose/HbA1c: around 4 months after initiation and then annually (more often if abnormal or high risk)
Lipid panel: around 4 months after initiation and then annually (more often if abnormal or high risk)
CBC: as clinically indicated; check more frequently early in therapy if preexisting low WBC or history of drug-induced leukopenia/neutropenia
Blood chemistries: electrolytes, renal function, liver function, and TSH as clinically indicated
Prolactin: ask about symptoms at each visit until stable; check levels if symptoms occur (menstrual changes, libido changes, gynecomastia, galactorrhea, sexual dysfunction)
ECG: baseline and as clinically indicated in older adults and patients with preexisting cardiac disease or conduction risk
Serum sodium: in at-risk populations (especially older adults) when clinically indicated; watch for hyponatremia/SIADH symptoms (confusion, weakness, falls)
Temperature regulation: monitor risk with heat exposure, dehydration, strenuous activity, and anticholinergic stacking
Ocular effects: ocular exam as clinically indicated; consider risk with long-term phenothiazine exposure and in patients with diabetes or vision concerns
Therapeutic drug monitoring (optional/selected cases): trough levels can help confirm adherence; dosing should still be based on clinical response and tolerability

Available Formulations

Tablet (Oral): amitriptyline HCl 10 mg / perphenazine 2 mg
Tablet (Oral): amitriptyline HCl 10 mg / perphenazine 4 mg
Tablet (Oral): amitriptyline HCl 25 mg / perphenazine 2 mg
Tablet (Oral): amitriptyline HCl 25 mg / perphenazine 4 mg
Tablet (Oral): amitriptyline HCl 50 mg / perphenazine 4 mg

Mechanism of Action

Amitriptyline increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibiting their reuptake. Perphenazine is a piperazine phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic receptors; it also has alpha-adrenergic blocking effects and influences hypothalamic/pituitary hormone signaling. In plain terms: one part pushes antidepressant signaling, the other part dampens dopamine-driven agitation/psychotic symptoms—together aiming to reduce depression plus agitation/anxiety.

Place in Treatment Algorithm

This is not a modern first-line “default” option for depression or anxiety. It’s a higher-side-effect combination that may be considered when depression is paired with significant anxiety/agitation and a sedating approach is clinically appropriate, or when schizophrenia includes depressive symptoms. The downside is predictable: anticholinergic burden, orthostatic hypotension/falls, cardiac conduction risks, and typical antipsychotic movement side effects. In older adults, it’s usually avoided unless the situation is unusually specific and benefits clearly outweigh harms.

Frequently Asked Questions

What is amitriptyline/perphenazine used for?

In psychiatry, it’s used for unipolar major depression when anxiety and/or agitation are moderate to severe, and for schizophrenia with depressive symptoms. It’s basically an antidepressant plus an antipsychotic in one tablet—meant for situations where “depression + agitation/anxiety” is the real target.

Is this medication approved for kids or teens?

No. Per the provided safety information, this combination is not approved for pediatric patients. Antidepressants also carry a boxed warning about increased risk of suicidal thinking/behavior in children, adolescents, and young adults, so pediatric prescribing requires extreme caution and close monitoring—this combo isn’t the go-to.

Does it help anxiety?

It can help anxiety symptoms that come along with depression—especially when anxiety looks like agitation, insomnia, and feeling keyed-up. It’s not typically used as a standalone anxiety medication, and the side effect burden is heavier than many modern options.

How is it usually dosed for depression with anxiety/agitation?

A common starting approach is 1 tablet three or four times daily of amitriptyline 25 mg/perphenazine 2 mg or 4 mg, or 1 tablet of amitriptyline 50 mg/perphenazine 4 mg twice daily. Doses are adjusted based on response and tolerability, with a maximum daily dose of amitriptyline 200 mg and perphenazine 16 mg in divided doses.

What if my symptoms are mostly anxiety rather than depression?

If anxiety is predominant, lower starting doses may be considered—like 1 tablet of amitriptyline 10 mg/perphenazine 4 mg three to four times daily. The idea is to reduce side effects while still getting a calming effect.

What are the most common side effects people notice?

Sedation and slowed thinking, dry mouth, constipation, dizziness when standing (orthostatic hypotension), and movement side effects (restlessness/akathisia, stiffness, tremor). If you get severe restlessness, new abnormal movements, or you feel faint, that’s not something to ignore.

What’s the big boxed warning I should know about?

There are two. (1) Antidepressants can increase suicidal thinking/behavior in children, adolescents, and young adults (especially early in treatment and with dose changes). Everyone starting antidepressants should be monitored for worsening depression, suicidality, and unusual behavior changes. (2) Antipsychotics increase mortality risk in elderly patients with dementia-related psychosis—this medication is not approved for dementia-related psychosis.

Can I take it with an MAOI?

No. You need a washout period. Allow 14 days between stopping an MAOI and starting amitriptyline/perphenazine, and allow 14 days between stopping amitriptyline/perphenazine and starting an MAOI.

Why is it usually avoided in older adults?

Because it stacks multiple risks: strong anticholinergic effects (confusion, constipation, urinary retention), sedation, orthostatic hypotension and falls, hyponatremia risk, plus antipsychotic risks (stroke/cognitive decline and increased mortality in dementia-related psychosis). In many older adults, the harm potential outweighs the benefit.

How do you stop it safely?

Usually by tapering rather than stopping abruptly—unless there’s a safety emergency. Stopping suddenly can trigger discontinuation symptoms (nausea, dizziness, insomnia, anxiety, irritability) and can also cause rebound symptoms from the antipsychotic side. Taper speed depends on dose, duration, and how your body reacts.

What should I watch for that needs urgent medical attention?

High fever with severe muscle stiffness and confusion (possible NMS), severe fainting, chest pain or palpitations with severe dizziness, inability to urinate, severe constipation with abdominal pain, signs of infection (fever/sore throat) that could signal a blood problem, or rapidly worsening suicidal thoughts—especially early in treatment or after dose changes.

This medication information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Never take medication without a prescription from a licensed healthcare provider.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists

Amitriptyline/Perphenazine

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published December 9, 2025•Updated December 9, 2025•Reviewed December 9, 2025